Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

RCT (n=144) found no significant difference in median time to vaso-occlusive crisis resolution between this novel non-anticoagulant low molecular weight heparinoid with anti-adhesive properties and placebo (100.4 vs 86.4 hours, respectively, HR 0.89; 95% CI, 0.6–1.3; p=0.55).

Source:

The Lancet Haematology